Evidence map›Paper›PMID 38104255›Full record

ArticleSchizophrenia bulletin2024

The PSY-SIM Model: Using Real-World Data to Inform Health Care Policy for Individuals With Chronic Psychotic Disorders.

Claire de Oliveira, Joyce Mason, Linda Luu, Tomisin Iwajomo, Frances Simbulan, Paul Kurdyak, Petros Pechlivanoglou

Open access · bronzeAbstract read
In one paragraph

Article in Schizophrenia bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Claire de OliveiraInstitute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.ORCID 0000-0003-3961-6008
Joyce MasonInstitute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.ORCID 0000-0002-2113-2198
Linda LuuChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
Tomisin IwajomoInstitute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.ORCID 0000-0003-1616-5267
Frances SimbulanInstitute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.ORCID 0009-0008-5555-690X
Paul KurdyakInstitute for Mental Health Policy Research and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.ORCID 0000-0001-8115-7437
Petros PechlivanoglouICES, Toronto, Ontario, Canada.ORCID 0000-0001-5090-7936
Centre for Addiction and Mental Health · CAUniversity of Toronto · CAHospital for Sick Children · CA

Funding

Canadian Community Health SurveyOntario Ministries of Health and Long-term Care
6 · The paper itself

Abstract

background and hypothesisFew microsimulation models have been developed for chronic psychotic disorders, severe and disabling mental disorders associated with poor medical and psychiatric outcomes, and high costs of care. The objective of this work was to develop a microsimulation model for individuals with chronic psychotic disorders and to use the model to examine the impact of a smoking cessation initiative on patient outcomes. STUDY

designUsing health records and survey data from Ontario, Canada, the PSY-SIM model was developed to simulate health and cost outcomes of individuals with chronic psychotic disorders. The model was then used to examine the impact of the Smoking Treatment for Ontario Patients (STOP) program from Ontario on the development of chronic conditions, life expectancy, quality of life, and lifetime health care costs. STUDY

resultsIndividuals with chronic psychotic disorders had a lifetime risk of 63% for congestive heart failure and roughly 50% for respiratory disease, cancer and diabetes, and a life expectancy of 76 years. The model suggests the STOP program can reduce morbidity and lead to survival and quality of life gains with modest increases in health care costs. At a long-term quit rate of 4.4%, the incremental cost-effectiveness ratio of the STOP program was $41,936/QALY compared with status quo.

conclusionsSmoking cessation initiatives among individuals with chronic psychotic disorders can be cost-effective. These findings will be relevant for decision-makers and clinicians looking to improving health outcomes among this patient population.

Indexed as

Psychotic DisordersSmoking CessationAdultAgedChronic DiseaseComputer SimulationCost-Benefit AnalysisFemaleHealth Care CostsHealth PolicyHumansLife ExpectancyMaleMiddle AgedOntarioQuality-Adjusted Life Yearschronic psychotic disordersmicrosimulationpsychosisschizophreniasmoking cessation

Identifiers

PMID38104255
PMCPMC11349024
OpenAlexW4389900021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.